Business UpdateSep 22, 2026, 04:08 PM
Biomea Fusion Updates BMF-650 Trial Results Timeline to October 2026
AI Summary
Biomea Fusion, Inc. (BMEA) has updated the expected timeline for topline results from its Phase I GLP-131 trial evaluating BMF-650 in obese, healthy volunteers. The company now anticipates these results will be available in October 2026. This update pertains to the ongoing clinical trial for their drug candidate.
Key Highlights
- Biomea Fusion updated the anticipated timing for topline results from its ongoing Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers.
- Topline results are now expected in October 2026.
Price Impact
More from BMEA
Quarterly ResultAug 5, 4:19 PM
Biomea Fusion Q2 Net Loss Narrows to $8.3M; Going Concern Doubt Raised
Quarterly ResultAug 5, 4:09 PM
Biomea Fusion Reports Q2 Net Loss $8.3M; Advances Diabetes & Obesity Trials
Clinical TrialJun 5, 7:33 PM
Biomea Fusion Icovamenib Data Shows T1D/T2D Benefits, Metabolic Health